FDA approves revised medication guide for Coumadin

Share this article:
The FDA has approved a revised medication guide and labeling for Bristol-Myers Squibb's blood thinner Coumadin (warfarin sodium) to more prominently emphasize a warning about the risk of major or fatal bleeding.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.